PARP inhibitors, such as rucaparib, have been well characterized in metastatic castration-resistant prostate cancer (mCRPC) associated with BRCA alterations, and the clinical activity of these agents has also been evaluated in patients with mCRPC associated with alterations in other non-BRCA DNA damage repair (DDR) genes, including RAD51B. There is likely a differential sensitivity to PARP inhibition based on the specific DDR gene altered, but research in this area is limited because of the low frequency of alterations in these genes. Here, we describe a mCRPC patient with a truncating rearrangement of RAD51B who had a radiographic and PSA response when treated with the PARP inhibitor rucaparib within the TRITON2 trial. We investigated the patients' response parameters, circulating tumor DNA (ctDNA) fraction and tumor genomics longitudinally, using next-generation sequencing (NGS) of tissue and plasma. ctDNA fraction correlates with radiographic and PSA response and is lower during times of response. NGS did not reveal any potential genomic mechanism of acquired drug resistance. This case shows evidence for rucaparib activity in a rare patient with mCRPC and a RAD51B truncation.
Current oncology (Toronto, Ont.). 2022 Jun 08*** epublish ***
Brieuc Sautois, Andrea Loehr, Simon P Watkins, Hélène Schroeder, Wassim Abida
Medical Oncology, University Hospital of Liège, CHU Sart Tilman, 4000 Liège, Belgium., Translational Medicine, Clovis Oncology Inc., Boulder, CO 08006, USA., Clinical Science, Clovis Oncology UK, Ltd., Cambridge CB21 6GP, UK., Genitourinary Oncology Service, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.